Search Results

Palisade Bio, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET.

Palisade Bio, Inc. announced it has appointed Margery Fischbein to its Board of Directors.

Palisade Bio, Inc. announced that it will present at the Virtual Investor Lunch Break Featuring Palisade Bio event on Tuesday, April 16, 2024 at 12:00 PM ET.

Palisade Bio, Inc. today provided an update on key areas of progress for its previously announced strategic collaboration with Strand Life Sciences (“Strand”), a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

Palisade Bio, Inc. today reported its financial results for the first quarter 2024 and provided a business update.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.”

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

Palisade Bio, Inc. today provided a corporate update and reiterated upcoming milestones.